Program
fetrastobart vedotin
In Pfizer’s pipeline, PD-L1-directed antibody-drug conjugate
. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Pfizer.
Furthest: phase 3, since Aug 20, 20252 company-led studies, 2 open or runningNext primary completion: Jan 5, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 22 open or running | phase 3since Aug 20, 2025 | Dec 15, 2021 | Jan 5, 2028phase 1 · NCT05208762 |
- Named in Pfizer’s own pipeline as
fetrastobart vedotin PF-08046054
, phase 3, as of Nov 3, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 15, 2021First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT05208762 · 714 planned · United States, Belgium, Canada and more
- Aug 20, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07144280 · 680 planned · United States, Argentina, Australia and more
Ahead
- Jan 5, 2028Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT05208762
- Mar 10, 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07144280
TargetBeta
“PD-L1-directed antibody-drug conjugate”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of fetrastobart, an antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), conjugated to the cytotoxic agent monomethyl auristatin E (MMAE) via a protease-cleavable peptide l…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of fetrastobart, an antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), ”NCIt, by rule
Other programs on CD274
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| durvalumabrule | AstraZeneca | phase 4 | 102 |
| adebrelimabrule | Jiangsu HengRui Medicine | phase 3 | 51 |
| pumitamig | BioNTech | phase 3 | 34 |
| benmelstobartrule | Sino Biopharmaceutical | phase 3 | 33 |
| retlirafusp alfarule | Jiangsu HengRui Medicine | phase 3 | 20 |
| Anti-PD-L1 Antibody-drug Conjugate HLX43 | Fosun Pharma | phase 3 | 17 |
| erfonrilimabrule | Alphamab Oncology | phase 3 | 14 |
| Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rule | nanjing-leads-biolabs-co-ltd | phase 3 | 10 |
| socazolimabrule | Lee's Pharmaceutical | phase 3 | 9 |
| acasunlimabrule | Genmab | phase 3 | 6 |
| sotiburafusp alfarule | huabo-biopharm-co-ltd | phase 3 | 5 |
| HLX37 | Fosun Pharma | phase 3 | 2 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07144280Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Mar 10, 2028 | 680 |
| NCT05208762Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more | 1 | Recruiting | Jan 5, 2028 | 714 |
How it is read
Names in the registry
- “PF-08046054”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.